Clinical Trials Directory

Trials / Completed

CompletedNCT01723787

Genetic Studies in Patients and Families With Infantile Spasms

Status
Completed
Phase
Study type
Observational
Enrollment
63 (actual)
Sponsor
University of Colorado, Denver · Academic / Other
Sex
All
Age
31 Days – 21 Years
Healthy volunteers
Not accepted

Summary

Infantile spasms (IIS), a characteristic epilepsy syndrome of infancy with often catastrophic developmental consequences, is known in some patients to have many different genetic, metabolic and structural etiologies. However, for most patients IIS is the only presenting clinical feature and the specific cause is unknown. Only two FDA approved pharmacologic treatments for IIS exist, Adrenocorticotropic hormone (ACTH) and vigabatrin. While vigabatrin may be the treatment of choice for Tuberous Sclerosis as a cause for IS, ACTH is the treatment of choice for all others. Unfortunately, a substantial number of patients may still not respond to ACTH and there is no a priori way that suggests which patients may be responders. This has led to the following key questions: Can novel genetic analyses determine known genetic causes of IS with greater efficiency (more timely and cost-effective)? Can novel genetic analyses determine previously unknown disease modifying genes that predispose individuals to develop IS? Can novel genetic analyses elaborate genes and gene polymorphisms that favor ACTH responsiveness? Do these polymorphisms suggest strategies to improve ACTH responsiveness?

Detailed description

Primary Aim 1: Apply whole-exome sequencing to determine possible causes of cryptogenic IS and evaluate adding whole-exome sequencing to standard practice for determining causes of IS. Sub-aim 1: Determine the effectiveness of whole-exome sequencing in suggesting disease-modifying genes that may contribute to triggering IS. Primary Aim 2: Determine genes, through whole-exome sequencing, that may play a role in determining ACTH responsiveness for IS. Sub-aim 2: Correlate genes or genetic factors (haplotypes) associated with ACTH responsiveness and disease modification.

Conditions

Timeline

Start date
2013-03-01
Primary completion
2017-03-09
Completion
2018-11-30
First posted
2012-11-08
Last updated
2021-06-14

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01723787. Inclusion in this directory is not an endorsement.